Ono Pharmaceutical said on August 28 that it has submitted a regulatory application for its BTK inhibitor tirabrutinib (ONO-4059) in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma (PCNSL). Since the drug is granted orphan…
To read the full story
Related Article
- Ono’s BTK Inhibitor Hits ORR of 88.9% in Types of B Cell Lymphomas: Japan PII
December 10, 2019
- Ono Files Tirabrutinib for Add’l Indications in Japan
November 28, 2019
BUSINESS
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
- Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
August 26, 2026
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
- Astellas Starts Global PIII of ASP2138 in Gastric Cancer
August 26, 2026
- Chugai Files Vamikibart in Japan for Uveitic Macular Edema
August 26, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





